Virtual Library
Start Your Search
N. Molinas Mandel
Author of
-
+
P1.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 212)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.03-025 - Relation of Visceral Pleura Invasion with Hilar Lymph Node Involvement and Survival in Primary Lung Cancer (ID 1328)
09:30 - 09:30 | Author(s): N. Molinas Mandel
- Abstract
Background:
The aim of this study is to investigate the role of visceral pleura invasion on hilar lymph node involvement and survival in surgically treated primary lung cancer patients.
Methods:
We examined pathological data of 219 surgically treated primary non-small cell lung cancer patients operated between january 2006 & March 2012. Patients were divided into three groups. Group 1: Patients with a tumor entrapped within the thick elastic layer (PL0), Group 2: Patients with tumor crossed the elastic layer of visceral pleura (PL1), Group 3: patients with a tumor crossed the elastic layer and reached the surface of visceral pleura (PL2). Patients with parietal pleura invasion (PL3) and operative mortality (45 patients) were excluded from the study. Groups were examined in terms of tumor size, mediastinal involvement, lymphovasculary invasionand survival.
Results:
Visceral pleura invasion (PL1 and PL2) was detected in 56 of 174 surgically treated patients (32.1%). In this group, PL1 was found in 43 patients (24.7%) and PL2 was found in 13 patients (7.4%). Mean follow-up was 48.68±27.47 months (4-106). We found that visceral pleura invasion statistically significantly reduce survival independently from hilar/mediastinal lymph node involvement (N1-N2) and tumor size (mean survival 53.78±28.91 vs 37.95±20.54 months, p=0.001). Also we found that the ratio of the presence of hilar lymph node involvement with visceral pleura invasion is statistically higher than the group without visceral pleura invasion (30.9% vs 18.1% p=0.03). There were no statistically significance in terms of survival between the groups PL1 and PL2 (mean survival 39.23±20.01 vs 33.69±22.49 p=0.39).
Conclusion:
We should consider adjuvant treatment independently from tumor size and lymph node involvement for patients with visceral pleura invasion.
-
+
P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.08-023 - Induction Chemotherapy Increases the Survival of Patients with Primary Neuroectodermal Tumors of the Thorax (ID 2415)
09:30 - 09:30 | Author(s): N. Molinas Mandel
- Abstract
Background:
Primary neuroectodermal tumors (PNETs) of the thorax are rare, small-round cell tumors with a poor prognosis despite multimodal therapy, including surgery and chemoradiotherapy. The ideal treatment was unknown since no comparative clinical series with surgical therapy had been reported. We evaluated the results of multimodal treatment in patients with PNETs located in the thoracic region.
Methods:
Between 2000 and 2013, 27 patients with PNETs in the thoracic region were treated in 3 tertiary-care hospitals. There were 15 males and 10 females with a mean age of 26.3 years (range, 6 – 60). The tumor was located in the chest wall in 21 (involving the costovertebral junction in 7), the lung in 6 patients. Thirteen patients had induction chemotherapy, whereas 22 patients underwent resectional surgery. All the patients received adjuvant chemo/radiotherapy.
Results:
There was no hospital mortality. The overall 5-year survival rate was 42% and median survival was 36±14 months in all patients. Five year survival in patients who had induction chemotherapy was 56%, whereas it was 36% in cases who did not receive induction chemotherapy (p=0.045). The 5-year survival rate of patients with and without costovertebral junction involvement was 21% and 64%respectively(p=0.076). The 5-year survival in the patients who had pulmonary involvement without vertebral or chest wall invasion had 50%.
Conclusion:
Primary thoracic PNET is an aggressive entity that often requires multimodal therapy. Induction chemotherapy seems to lead a greater complete resection rate and better survival, while involvement of the costovertebral junction indicates a slightly worse prognosis.
